FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
20/02/2023
Voltar para busca
Dado oficial do USPTO
TICEBA STEM CELL EXPERTS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
TICEBA STEM CELL EXPERTS
ST13
US500000079311207Classe
1, 5, 42, 44
Pedido
79311207
Registro
6861489
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
20/02/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44
Data de depósito
22/12/2020
Data de registro
04/10/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/10/2022
Última transação
04/10/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
01
Localização do titular
DE
Examinador
ROACH, APRIL
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
D. G. (pessoa física)
Representantes
Sean K. Owens Wood Herron & Evans LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Stem cells for scientific or research use; cell growth media for growing cells for scientific use
Classe 5
pharmaceutical drugsnamely pharmaceutical drugs for treatment of skin diseasesantibioticsimmune suppressantsanti-inflammatory pharmaceuticals; pharmaceutical drugs for treatment of disease and disorders of the respiratory systemthe gastrointestinal systemthe endocrine systemthe cardiovascular systemthe nervous systemthe musculoskeletal systemthe urinary systemthe integumentary systemthe reproductive systemfor the treatment of blood diseases and disorders; pharmaceutical drugs for treatment of cancerhormone replacement therapy preparations; pharmaceutical and veterinary preparations for treatment of vertigomigrainenauseavomitingfor treatment of skin diseaseswound healingpharmaceutical and veterinary preparations for treating diabetesantidepressants; pharmaceutical preparations for anti-agingpharmaceutical preparations namely antibioticsvaccines; diagnostic agents for medical use; preparations for medical purposesfor the treatment of skin diseasesallergy medicationherbal extracts for medical usereagents for medical use; substances for medical usefor regeneration of tissue and anti-inflammation; stem cells for medical purposes; stem cells for veterinary purposes; stem cells for aesthetic purposesfor anti-agingfor use in dermatology procedures; somatic stem cell therapeuticsfor medical therapeutic use; fibroblasts for medical use; fibroblasts for aesthetic purposesfor use in dermatology procedures; pharmaceutical implantsimplantable subcutaneous drug delivery devices sold filled with pharmaceutical for treatment of skin diseasesblood diseasesvertigonauseavomitingmigrainerespiratory systemthe gastrointestinal systemthe endocrine systemthe cardiovascular systemthe musculoskeletal systemthe urinary systemthe integumentary systemthe reproductive system; surgical implants derived from stem cellssurgical implants derived from living tissues and living stem cells; surgical implants derived from fibroblastssurgical implants comprised of living fibroblasts tissue cells; biological tissue for implantationimplants comprising living tissues; cell growth media for growing cells for medical use; pharmaceutical preparations for tissue regeneration; vascular grafts; living tissuesurgical implants comprised of living tissues; biotechnologically engineered tissue productsliving tissue cell sheets and plasters for wound healing and burnsbiological eye lens graftsbone grafts in the nature of biological bone tissue for graftingbiological tissue graftshuman allograft tissue
Classe 42
Stem cell research; scientific research and development and medical research and development in the field of stem cellsvaccines and medications; scientific researchtesting and analysis services in the field of regenerative medicine and tissue engineeringgenetics and genetic engineering; scientific research for medical purposes; medical research; research and development of new products for others; consultancy in the field of pharmaceutical research; providing information on medical and scientific research on pharmaceutical products; biomedical research; preparation of reports relating to scientific researchtechnical writing for others; research in the field of biotechnology; research in the field of gene therapy; research and development in the field of immunology; research and development in the field of antibodies; research and development in the field of antibody technology; research and development in the field of bacteriology; research and development in the field of gene expression systems; research and development in the field of vaccines; research and development services for the pharmaceutical industry; research and development services in the field of biotechnology; development of industrial processesengineering of industrial processes in the field of for packagingstorage and transport of human tissue and human adult ancestral cellsengineering of industrial processes to manufacture stem cells; industrial process research in the field of regenerative medicine and tissue engineeringchemical engineering
Classe 44
Medical services relating to the removaltreatmentprocessing and preservation of human bloodcord bloodhuman cells and tissuestem cells and bone marrowalso in the field of regenerative medicineincluding tissue engineering; medical services in connection with the removaltreatment and processing of human tissue and stem cellshuman tissue and stem cell bank servicesincluding in the field of regenerative medicineincluding tissue engineering; medical services relating to the cultivation and extraction of stem cells; medical services in connection with the cultivation and extraction of stem cells
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
26/01/2023
FIMP
FINAL DISPOSITION PROCESSED
26/01/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/01/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/10/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
04/10/2022
GPNX
NOTIFICATION PROCESSED BY IB
25/07/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/07/2022
PUBO
PUBLISHED FOR OPPOSITION
19/07/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
29/06/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
29/06/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/06/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/06/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/06/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/06/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
08/06/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
22/12/2021
GNFR
FINAL REFUSAL E-MAILED
22/12/2021
CNFR
FINAL REFUSAL WRITTEN
22/12/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/12/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/12/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/12/2021
RFNT
REFUSAL PROCESSED BY IB
19/07/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
28/06/2021
RFRR
REFUSAL PROCESSED BY MPU
28/06/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/06/2021
CNRT
NON-FINAL ACTION WRITTEN
17/06/2021
DOCK
ASSIGNED TO EXAMINER
16/06/2021
MAFR
APPLICATION FILING RECEIPT MAILED
25/05/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/05/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
20/05/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TICEBA STEM CELL EXPERTS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.